Review: terazosin improves urologic symptoms in benign prostatic hyperplasia.
نویسنده
چکیده
and commentary also appear in ACP Journal Club. Therapeutics EBM Volume 8 May/June 2003 83 www.evidence-basedmedicine.com group.bmj.com on August 27, 2017 Published by http://ebm.bmj.com/ Downloaded from
منابع مشابه
Ejaculatory Dysfunction Caused by Alpha Blockers for the Treatment of Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Systematic Review and Network Meta-analysis
To provide a systematic review and network meta-analysis of randomized clinical trials focus on ejaculatory dysfunction (ED) rate of alpha blockers (ABs) for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH), a systematic literature search was performed to identify all available published randomized controlled trial (RCTs) as regards ABs for the tre...
متن کاملBenign Prostatic Hyperplasia: from Bench to Clinic
Benign prostatic hyperplasia (BPH) is a prevalent disease, especially in old men, and often results in lower urinary tract symptoms (LUTS). This chronic disease has important care implications and financial risks to the health care system. LUTS are caused not only by mechanical prostatic obstruction but also by the dynamic component of obstruction. The exact etiology of BPH and its consequences...
متن کاملEarly Efficacy of Tamsulosin Versus Terazosin in the Treatment of Men With Benign Prostatic Hyperplasia: A Randomized, Open-Label Trial
Background: We evaluated the efficacy and tolerability of tamsulosin versus terazosin in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Methods: Patients (N = 1,993) were randomized to tamsulosin (0.4 mg/day) or terazosin (5 mg/day, following titration). The primary efficacy endpoint was total American Urological Association Symptom Index (AUA-SI) score after 4 days of ...
متن کاملTherapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments
Therapeutic Class Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) will be the focus of this review. The α-adrenergic blockers including, alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate and bladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzo...
متن کاملMedical therapy for benign prostatic hyperplasia: a review of the literature.
OBJECTIVE To review the existing evidence regarding the efficacy and safety of medical therapy for lower urinary tract symptoms (LUTS) indicative of benign prostatic hyperplasia (BPH). To assess randomised controlled trials investigating the six alpha-adrenergic receptor antagonists (alpha-blockers), prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin, that benefit patients by ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- ACP journal club
دوره 138 3 شماره
صفحات -
تاریخ انتشار 2003